Literature DB >> 14598082

Levodopa pharmacokinetics and dyskinesias: are there sex-related differences?

P Martinelli1, M Contin, C Scaglione, R Riva, F Albani, A Baruzzi.   

Abstract

We examined the potential sex-related differences in levodopa pharmacokinetics and their relation with the presence of dyskinesias in a group of 115 patients (67 men, 49 women) with Parkinson's disease. The patients were given a standard oral dose of levodopa plus benserazide (100/25 mg). The area under the levodopa plasma concentration time curve, corrected for the levodopa test dose (in mg/kg body weight), (AUC(w)) was significantly higher in women than in men, with a reduced oral clearance. No difference in the proportion of men and women experiencing dyskinesias was observed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14598082     DOI: 10.1007/s10072-003-0125-z

Source DB:  PubMed          Journal:  Neurol Sci        ISSN: 1590-1874            Impact factor:   3.307


  12 in total

1.  IPX066: a new intermediate-and extended-release carbidopa-levodopa formulation.

Authors:  Talene A Yacoubian
Journal:  Neurodegener Dis Manag       Date:  2013-04-01

Review 2.  Neurotrophic and neuroprotective actions of estrogen: basic mechanisms and clinical implications.

Authors:  Darrell W Brann; Krishnan Dhandapani; Chandramohan Wakade; Virendra B Mahesh; Mohammad M Khan
Journal:  Steroids       Date:  2007-02-21       Impact factor: 2.668

Review 3.  The relevance of gender in Parkinson's disease: a review.

Authors:  Marina Picillo; Alessandra Nicoletti; Vincenza Fetoni; Barbara Garavaglia; Paolo Barone; Maria Teresa Pellecchia
Journal:  J Neurol       Date:  2017-01-04       Impact factor: 4.849

4.  The "gender factor" in wearing-off among patients with Parkinson's disease: a post hoc analysis of DEEP study.

Authors:  Delia Colombo; Giovanni Abbruzzese; Angelo Antonini; Paolo Barone; Gilberto Bellia; Flavia Franconi; Lucia Simoni; Mahmood Attar; Emanuela Zagni; Shalom Haggiag; Fabrizio Stocchi
Journal:  ScientificWorldJournal       Date:  2015-01-20

Review 5.  Pharmacokinetics of Rytary®, An Extended-Release Capsule Formulation of Carbidopa-Levodopa.

Authors:  Aravind Mittur; Suneel Gupta; Nishit B Modi
Journal:  Clin Pharmacokinet       Date:  2017-09       Impact factor: 6.447

Review 6.  Parkinson's Disease in Women and Men: What's the Difference?

Authors:  Silvia Cerri; Liudmila Mus; Fabio Blandini
Journal:  J Parkinsons Dis       Date:  2019       Impact factor: 5.568

7.  Predictors of motor complications in early Parkinson's disease: A prospective cohort study.

Authors:  Mark J Kelly; Michael A Lawton; Fahd Baig; Claudio Ruffmann; Thomas R Barber; Christine Lo; Johannes C Klein; Yoav Ben-Shlomo; Michele T Hu
Journal:  Mov Disord       Date:  2019-07-08       Impact factor: 10.338

8.  Treatment Responsiveness of Motor Features in Parkinson's Disease: A Matched Case-Control Analysis.

Authors:  Angus D Macleod; Carl E Counsell
Journal:  Mov Disord Clin Pract       Date:  2019-11-21

Review 9.  Pharmacokinetic optimisation in the treatment of Parkinson's disease : an update.

Authors:  Dag Nyholm
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 5.577

10.  Population pharmacokinetics of levodopa in subjects with advanced Parkinson's disease: levodopa-carbidopa intestinal gel infusion vs. oral tablets.

Authors:  Ahmed A Othman; Sandeep Dutta
Journal:  Br J Clin Pharmacol       Date:  2014-07       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.